Tuclazepam
Tuclazepam is a drug of the benzodiazepine class. It is one of the benzodiazepines developed by Hoffmann-La Roche in the 1960s and 1970s. Tuclazepam has sedative and anxiolytic effects.
History[edit]
Tuclazepam was developed by a team at Hoffmann-La Roche in the 1960s and 1970s. The team was led by Leo Sternbach, who is credited with the discovery of the benzodiazepine class of drugs. Tuclazepam is one of several benzodiazepines developed by Hoffmann-La Roche during this period, including diazepam, clonazepam, and flurazepam.
Pharmacology[edit]
Like other benzodiazepines, tuclazepam works by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain. This results in sedative, anxiolytic, anticonvulsant, and muscle relaxant effects.
Tuclazepam is metabolized in the liver by the cytochrome P450 enzyme system. It has a half-life of approximately 8 hours. The drug is excreted in the urine, primarily as its glucuronide conjugate.
Medical uses[edit]
Tuclazepam is used primarily for the treatment of anxiety disorders. It may also be used for the short-term relief of symptoms of anxiety, or anxiety associated with depressive symptoms. Like other benzodiazepines, it is not recommended for use in those with a history of substance abuse or dependence.
Side effects[edit]
Common side effects of tuclazepam include drowsiness, dizziness, and impaired coordination. Less common side effects may include confusion, depression, and changes in libido. Long-term use of tuclazepam can lead to tolerance, dependence, and withdrawal symptoms upon discontinuation.
See also[edit]
